

Impression Undertakes \$2.2M Capital Raise Initiative

Australia's largest home dental impression company, Impression Healthcare Limited ('Impression' or 'the Company') is pleased to announce that it has executed a capital raise mandate with Alignment Capital Pty Ltd ('Alignment') to raise a total of \$2.2m by way of three separate funding initiatives:

- an entitlement-based Rights Issue by way of prospectus;
- a post-Rights Issue placement; and
- \$750,000 via a fully subscribed converting loan offer.

Rights issue

In the coming days, Impression will dispatch the Rights Issue prospectus to Shareholders on the basis that Shareholders may buy one new share in the Company for every four (1:4) shares held at the Record Date for a subscription price of \$0.01 per new share. This will result in the Company issuing approximately 73.5m new shares to raise \$735,721.

The Record Date for entitlement to Rights will be 7.00pm (AEST) on Wednesday, 26 September 2018. In deciding whether to acquire further shares, a shareholder should consider the contents of the prospectus and will need to complete the application form that will accompany the prospectus.

Any Rights Issue Shortfall will be placed into the market by Alignment on a 'best endeavours' basis.

Placement

Following the Rights Issue, Impression may place up to a further 73.5m new shares in a proposed placement to professional and sophisticated investors at \$0.01 per share to raise up to \$735,000 ("wholesale placement"). Under the terms of the mandate, Impression will have three months post the closing date of the Rights Issue to issue any shortfall or wholesale placement shares.

Converting Loan

Subscribers to the converting loan facility totalling \$750,000 will receive an interest payment of 10% of the subscription value. The principal and interest will convert into fully paid ordinary IHL shares, at the Company's discretion, at \$0.01 per share. Subscribers will also receive one IHLOB listed option for each fully paid ordinary IHL share converted. Amounts not converted will be repaid in cash to Subscribers.

Shares that could potentially be issued under the converting loan facility and wholesale placement will be voted on by Shareholders at the Company's upcoming AGM which will be scheduled for late October 2018.

No shares will be issued subject to the terms of the convertible loan unless Shareholder approval has been obtained. In the event that the loan conversion is not approved by Shareholders, the loan will remain as a debt instrument until repaid or converted when sufficient issue capacity under listing rules 7.1 and/or 7.1A allows.

For personal use only

About Alignment

Alignment is a boutique broker specialising in finance and funding arrangements for small and microcap companies (www.alignmentcapital.com.au). Alignment is an entity in respect of which Mr Troy Valentine (a Director of the Impression) is a director and major shareholder.

Alignment will receive market-rate fees because of the mandate and may choose to accept shares in lieu of cash fees owed in whole or in part, subject to the requirements of the ASX listing rules.

Application of funds

Funds raised from the rights issue and converting loan are expected to be applied towards the following activities:

- to continue cost-effective growth of the oral health-care devices business (\$600,000); and
- to repay existing Convertible Note debt (plus accrued interest) due in two instalments payable in October 2018 and January 2019 (\$300,000); and
- for general working capital of the Company (\$400,000); and
- to support the collaboration initiative with AXIM Biotechnologies Incorporated (\$150,000)

If approved by Shareholders, funds from the wholesale placement will be applied in a similar manner and in similar proportions.

Furthermore, Impression expects to receive an R&D rebate in the December quarter totalling approximately \$300k.

Indicative Timetable for Rights Issue

Event	Date
Lodgement of Prospectus with ASIC and ASX	19 September 2018
"Ex" Date	25 September 2018
Record Date (at 7:00pm AEST)	26 September 2018
Prospectus and Application Form dispatched to Eligible Shareholders	1 October 2018
Offers Opening Date	1 October 2018
Rights Offer Closing Date (at 5:00pm AEST)	17 October 2018
Notification of Shortfall	18 October 2018
Issue of New Shares	22 October 2018

ENDS

For personal use only



Date: 19 September 2018
ASX Announcement (ASX: IHL)

About Impression Healthcare Limited (ASX: IHL)

Impression Healthcare Limited is Australia's largest home dental impression company and is disrupting the dental devices market by providing consumers with an in-home method to consume laboratory-grade and personalised dental healthcare products at significantly lower prices than those offered by the traditional dental industry. Impression has significantly grown its distribution footprint and increased its revenues by 359% in the 2018 Financial Year. With its own dental laboratory in Victoria, Australia Impression offers best in class teeth protection and helps its customers combat bruxism, snoring, mild to moderate sleep apnoea and teeth discolouration with custom-fitted oral devices.

Impression is broadening its commitment to disruption in the healthcare sector by exploring opportunities in medicinal cannabis distribution and development, underpinned by a collaboration agreement with leading US Cannabinoid therapeutics Company, AXIM Biotechnologies Inc. AXIM is focused on research, development and production of oral health, pharmaceutical, nutraceutical and cosmetic products incorporating cannabinoids for a wide range of indications. Impression will leverage its oral health marketing activities to explore opportunities distribute a range of AXIM's over the counter and therapeutic products as public opinion of cannabinoid-based therapeutics steadily improves.

Investors: investors@impression.healthcare

Website: www.impression.healthcare

For personal use only